174 related articles for article (PubMed ID: 16397368)
21. [New bone density conservation agents for osteoporosis under research and development: Zoledronate].
Wada S; Fukawa T; Kamiya S
Nihon Rinsho; 2007 Nov; 65 Suppl 9():421-5. PubMed ID: 18161143
[No Abstract] [Full Text] [Related]
22. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
23. [New development in bisphosphonate treatment. Clinical significance of combinatorial therapies with bisphosphonates and parathyroid hormone for osteoporosis].
Takeuchi Y
Clin Calcium; 2009 Jan; 19(1):85-90. PubMed ID: 19122268
[TBL] [Abstract][Full Text] [Related]
24. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
Rosa J; Vanuga P; Payer J; Svobodník A
Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
[TBL] [Abstract][Full Text] [Related]
25. A once-yearly IV bisphosphonate for osteoporosis.
Obstet Gynecol; 2008 May; 111(5):1208-9. PubMed ID: 18448761
[No Abstract] [Full Text] [Related]
26. [Osteoporosis treatment].
Uebelhart B; Rizzoli R
Rev Med Suisse; 2006 Jan; 2(47):47-51. PubMed ID: 16465945
[TBL] [Abstract][Full Text] [Related]
27. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
28. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
Ohta H
Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
[TBL] [Abstract][Full Text] [Related]
29. [Combination therapy for osteoporosis].
Hagino H
Nihon Rinsho; 2007 Nov; 65 Suppl 9():316-20. PubMed ID: 18161124
[No Abstract] [Full Text] [Related]
30. Corticosteroids: no drug prevention of fractures needed.
Prescrire Int; 2009 Aug; 18(102):175. PubMed ID: 19746563
[TBL] [Abstract][Full Text] [Related]
31. Current and emerging therapies for osteoporosis.
Mitchner NA; Harris ST
J Fam Pract; 2009 Jul; 58(7 Suppl Osteoporosis):S45-9. PubMed ID: 19825319
[TBL] [Abstract][Full Text] [Related]
32. Fracture risk associated with chronic use of bisphosphonates: evidence today.
Charopoulos I; Orme S; Giannoudis PV
Expert Opin Drug Saf; 2011 Jan; 10(1):67-76. PubMed ID: 21121870
[TBL] [Abstract][Full Text] [Related]
33. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
[TBL] [Abstract][Full Text] [Related]
34. [Therapeutic considerations on secondary osteoporosis caused by diabetes mellitus].
Azuma K
Clin Calcium; 2009 Sep; 19(9):1345-52. PubMed ID: 19721208
[TBL] [Abstract][Full Text] [Related]
35. [Effects of SERMs on bone health. The potential of SERM in the care of chronic kidney disease-mineral bone and disorders].
Hamano T
Clin Calcium; 2010 Mar; 20(3):373-9. PubMed ID: 20190367
[TBL] [Abstract][Full Text] [Related]
36. Annual zoledronic acid for osteoporosis.
BMJ Group
Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701
[TBL] [Abstract][Full Text] [Related]
37. [Bisphosphonate].
Hagino H
Nihon Rinsho; 2015 Oct; 73(10):1683-9. PubMed ID: 26529930
[TBL] [Abstract][Full Text] [Related]
38. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
[TBL] [Abstract][Full Text] [Related]
39. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
40. [The successful development of bisphosphonates in the therapy of osteoporosis].
Fassbender WJ; Stumpf UC; Kurth A
Med Klin (Munich); 2006 Jun; 101 Suppl 1():6-14. PubMed ID: 16826363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
